Tempus AI, Inc.

Tempus AI is a healthcare technology company based in the United States. It offers the Tempus platform, a closed-loop, full-stack system that integrates a clinician's desktop with laboratory diagnostic capabilities, an analytics platform, and a repository of multimodal data. Its portfolio includes diagnostics services such as NGS diagnostics, PCR profiling, and anatomic and molecular pathology tests, with core assays like xT and xR for large-panel DNA and RNA testing. Additionally, it provides genetic tests for inherited conditions, pharmacogenomic testing for psychiatric conditions via its nP assay, and services like Insights for licensing de-identified clinical and molecular data, Organoids for tumor modeling, and Trials for clinical trial matching. The company also offers Next, an AI platform, and Algos, an algorithm-based diagnostics application.

Tempus AI is listed on the NasdaqGS exchange under the ticker symbol TEM. Its shares are traded in US Dollars (USD), as it is a United States-based company. The exchange is part of the Nasdaq stock market, which is one of the major stock exchanges in the world, and the company's listing there provides liquidity and visibility to global investors.

Tempus AI operates in the Healthcare sector, specifically within the Health Information Services industry. This industry focuses on using technology and data to improve healthcare delivery, and Tempus AI exemplifies this by providing a platform that integrates clinical and molecular data to support precision medicine. Its services range from diagnostic testing to AI-driven analytics, all aimed at enhancing patient care and research.

Tempus AI's main products and services include the Tempus platform, which offers bi-directional integrations between clinician desktops and lab diagnostics. Key offerings are Hub, a clinical application for NGS tests; Lens, a software for life sciences research; and diagnostics like NGS, PCR profiling, and anatomic pathology tests. Its core assays are xT and xR for solid tumors and hematologic cancers. The company also provides genetic tests for inherited conditions, the nP assay for pharmacogenomics in psychiatric care, and services such as Insights (data licensing), Organoids (tumor modeling), Trials (clinical trial matching), Next (AI platform), and Algos (algorithm-based diagnostics).

Tempus AI has strategic collaborations with several notable partners, including AstraZeneca AB, Pathos AI, Inc., and GlaxoSmithKline. These collaborations likely involve leveraging Tempus AI's platform and data capabilities to advance drug development, precision medicine, and clinical research. The partnerships highlight Tempus AI's role as a key player in integrating real-world data and AI into healthcare and pharmaceutical innovation.